Technology Review - Published By MIT
Advertisement

Using Molecular Pathways to Assess Cancer Patients

Continued from page 1

By Katherine Bourzac

Wednesday, October 17, 2007

smaller text tool iconmedium text tool iconlarger text tool icon

The protein-interaction map is then overlaid with a gene-expression profile from a breast-cancer patient's biopsy. Instead of looking at whether a patient with metastatic breast cancer is making more or less of one protein than a patient with a less aggressive form of the disease, the San Diego researchers were able to highlight protein pairs whose activity changed. They then looked for clusters in the interaction map where the activity level of a group of connected proteins was different in patients whose cancer eventually metastasized than in patients whose cancer did not. "Once you find the hot spots, you extract them from the hairball, and you have networks that correlate with metastasis," says Ideker.

Ideker's group discovered changes in the average activity of networks associated with the hallmarks of cancer, including metabolism, cell growth and division, and cell mobility. The researchers found that these changes in the activity of networks were better at predicting risk of metastasis than was analysis of gene-expression profiles alone. Looking at networks of proteins, "you see key changes you can't see looking at individual genes," says Collins. "Proteins rarely act individually."

Ideker says that he is currently in discussion with several companies about how to develop the network approach into a commercial test. However, he cautions that because his group tested its approach on preexisting gene-expression databases, it needs further testing in breast-cancer patients.

Ideker says that his group is already applying the protein network to other diseases, with promising early results. Collins agrees that the approach is generalizable, and he says that it may allow for early detection of diseases besides cancer.

Comments

  • mRNA abundance does not always equal protein abundance!
    If the "gene-expression profile" from the cancer patient's biopsy means using a microarray to measure the mRNA transcript abundance, it is important to note that the following sentence is scientifically incorrect:

    "They then looked for clusters in the interaction map where the activity level of a group of connected proteins was different in patients whose cancer eventually metastasized than in patients whose cancer did not."

    **mRNA transcript abundance does not equal protein abundance.  There is a 0.5-0.6 correlation (where 1.0 is a perfect correlation) between mRNA abundance and protein abundance for ~1/3 of the yeast genome.  This comparison has not been done for higher eukaryotes on a genome-wide scale. 

    **Just because a patient has higher levels of a particular mRNA transcript in their tumor biopsy sample does NOT mean that they are making more of that particular protein or that they have higher activity levels of that particular protein.  In fact, if we extrapolate from the yeast data, we would conclude that a patient with higher levels of a particular mRNA transcript would also have higher levels of that protein ONLY 50-60% OF THE TIME. 
    Rate this comment: 12345

    dmklass
    10/21/2007
    Posts:2

Log In

Forgot your password?     Register »
Advertisement

Videos

The Marcellus Shale Gas Rush
Technology Review November/December 2009

Current Issue

Natural Gas Changes the Energy Map
The United States has vast supplies of this cleaner fossil fuel. But how should we use it?
Advertisement
Advertisement
Subscribe to Technology Review's daily e-mail update. Enter your e-mail address

TECHNOLOGY RESOURCES

More Technology News from Forbes

Advertisement
MIT Massachusetts Institute of Technology © 2009 Technology Review. All Rights Reserved.